REG - Alliance Pharma PLC - Result of AGM

Alliance PharmaAnnouncement

18/05/2022 15:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220518:nRSR9931La&default-theme=true

RNS Number : 9931L  Alliance Pharma PLC  18 May 2022

 For immediate release  18 May 2022

 

 

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Result of AGM

 

Alliance Pharma plc (AIM: APH), the international healthcare group, announces
that, at its Annual General Meeting held earlier today, all the resolutions,
as set out in the Notice of Meeting, were duly passed on a poll.

 

The votes were as follows:

 

 RESOLUTION                           VOTES FOR    %       VOTES AGAINST  %      VOTES TOTAL  % OF ISC VOTED  VOTES WITHHELD
 1       Report and Accounts          371,393,469  99.99   30,000         0.01   372,087,366  68.97           663,897

 2       Final dividend               372,086,356  100.00  0              0.00   372,087,366  68.97           1,010

 3       Re-elect P. Butterfield      371,812,794  99.94   238,118        0.06   372,087,366  68.97           36,454

 4       Re-elect D. Cook             304,867,206  91.75   27,427,589     8.25   372,087,366  68.97           39,792,571

 5       Re-elect A. Franklin         371,701,797  99.91   346,094        0.09   372,087,366  68.97           39,475

 6       Re-elect R. Jones            318,832,469  94.70   17,845,835     5.30   372,087,366  68.97           35,409,062

 7       Re-elect J. LeCouilliard     283,289,848  84.14   53,391,477     15.86  372,087,366  68.97           35,406,041

 8       Elect K. Neirynck            371,168,677  99.76   882,235        0.24   372,087,366  68.97           36,454

 9       Re-appoint Auditor           372,018,741  99.99   38,636         0.01   372,087,366  68.97           29,989

 10      Remuneration of Auditor      372,058,198  100.00  2,200          0.00   372,087,366  68.97           26,968

 11      Allot shares                 314,847,187  84.62   57,236,109     15.38  372,087,366  68.97           4,070

 12      Disapply Pre-emption rights  318,400,733  85.57   53,682,363     14.43  372,087,366  68.97           4,270

The number of the Group's shares in issue as at the date of the meeting was
539,461,338 ordinary shares of 1p each.

Please note that each share carries one vote and that a 'vote withheld' is not
a vote in law and has not been counted in the calculation of the proportion of
the votes for and against the resolution. Any proxy appointments which gave
discretion to the Chairman have been included in the 'votes for' total.

Chris Chrysanthou

Head of Legal & Company Secretary

18 May 2022

 

For further information:

 

 Alliance Pharma plc                                                       + 44 (0)1249 466966
 Cora McCallum, Head of Investor Relations & Corporate Communications      + 44 (0)1249 705168
 ir@allianceph.com (mailto:ir@allianceph.com)

 Buchanan                                                                  + 44 (0)20 7466 5000
 Mark Court / Sophie Wills / Hannah Ratcliff
 alliancepharma@buchanan.uk.com (mailto:alliancepharma@buchanan.uk.com)

 Numis Securities Limited                                                  + 44 (0)20 7260 1000
 Nominated Adviser: Freddie Barnfield / Duncan Monteith
 Corporate Broking: James Black

 Investec Bank plc                                                         + 44 (0)20 7597 5970
 Corporate Finance: Daniel Adams
 Corporate Broking: Patrick Robb

 

 

About Alliance

 

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our
purpose is to improve the lives of consumers and patients through making
available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented
by a smaller Prescription Medicines business. In total, we hold marketing
rights to around 80 brands, with revenues generated from a mix of direct,
distributor and e-commerce sales.

Headquartered in the UK, Alliance employs around 250 people based in locations
across Europe, North America, and the Asia Pacific region. By outsourcing our
manufacturing and logistics operations, we remain asset-light and focused on
maximising the value of our brands.

For more information on Alliance, please visit our
website: www.alliancepharmaceuticals.com
(http://www.alliancepharmaceuticals.com/)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGBKFBQQBKDKPD